Indeed, we recently showed the feasibility of co-expressing in tumor-specific T-cells a bottleneck glycolytic enzyme, namely phosphofructokinase (PFK) together with GLUT3 and this led to superior anti-tumor activity (27). This evidence concerns the gene SLC2A3 and neoplasm.